Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    May 2019
  1. FAN C, Li M, Gan Y, Chen T, et al
    A simple AGED score for risk classification of primary liver cancer: development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China.
    Gut. 2019;68:948-949.
    PubMed     Text format    


    April 2019
  2. SHEN DT, Ji DZ, Chen HY, Goyal H, et al
    Hepatitis D: not a rare disease anymore: global update for 2017-2018.
    Gut. 2019 Apr 9. pii: gutjnl-2019-318691. doi: 10.1136/gutjnl-2019-318691.
    PubMed     Text format    


    March 2019
  3. ZHANG TY, Guo XR, Wu YT, Kang XZ, et al
    A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice.
    Gut. 2019 Mar 29. pii: gutjnl-2018-317725. doi: 10.1136/gutjnl-2018-317725.
    PubMed     Text format     Abstract available


    February 2019
  4. CANDOTTI D, Assennato SM, Laperche S, Allain JP, et al
    Multiple HBV transfusion transmissions from undetected occult infections: revising the minimal infectious dose.
    Gut. 2019;68:313-321.
    PubMed     Text format     Abstract available


    December 2018
  5. STOCKDALE AJ, Kreuels B, Henrion MRY, Giorgi E, et al
    Hepatitis D prevalence: problems with extrapolation to global population estimates.
    Gut. 2018 Dec 19. pii: gutjnl-2018-317874. doi: 10.1136/gutjnl-2018-317874.
    PubMed     Text format    


    November 2018
  6. LI H, Zhai N, Wang Z, Song H, et al
    Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection.
    Gut. 2018;67:2035-2044.
    PubMed     Text format     Abstract available


    October 2018
  7. WEDEMEYER H, Negro F
    Devil hepatitis D: an orphan disease or largely underdiagnosed?
    Gut. 2018 Oct 27. pii: gutjnl-2018-317403. doi: 10.1136/gutjnl-2018-317403.
    PubMed     Text format    


  8. YANG HC, Kao JH
    Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus.
    Gut. 2018 Oct 9. pii: gutjnl-2018-317385. doi: 10.1136/gutjnl-2018-317385.
    PubMed     Text format    


  9. LU XJ, Li XH, Yuan ZX, Sun HY, et al
    Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection.
    Gut. 2018;67:1903-1904.
    PubMed     Text format    


    September 2018
  10. LLIBRE A, Shimakawa Y, Duffy D
    Potential utility of the Genedrive point-of-care test for HCV RNA detection.
    Gut. 2018 Sep 22. pii: gutjnl-2018-317218. doi: 10.1136/gutjnl-2018-317218.
    PubMed     Text format    


  11. CHEN HY, Shen DT, Ji DZ, Han PC, et al
    Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis.
    Gut. 2018 Sep 18. pii: gutjnl-2018-316601. doi: 10.1136/gutjnl-2018-316601.
    PubMed     Text format     Abstract available


    August 2018
  12. GAO Y, Zhou Z, Ren T, Kim SJ, et al
    Alcohol inhibits T-cell glucose metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids.
    Gut. 2018 Aug 18. pii: gutjnl-2018-316221. doi: 10.1136/gutjnl-2018-316221.
    PubMed     Text format     Abstract available


  13. LOCARNINI S, Raimondo G
    How infectious is the hepatitis B virus? Readings from the occult.
    Gut. 2018 Aug 1. pii: gutjnl-2018-316900. doi: 10.1136/gutjnl-2018-316900.
    PubMed     Text format    


    July 2018
  14. LIM CJ, Lee YH, Pan L, Lai L, et al
    Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Gut. 2018 Jul 3. pii: gutjnl-2018-316510. doi: 10.1136/gutjnl-2018-316510.
    PubMed     Text format     Abstract available


    June 2018
  15. LEMOINE M, Tillmann HL
    What is required from HCV point-of-care tests to reduce the burden of hepatitis C infection? 'Development and clinical validation of the genedrive point-of-care test for qualitative detection of hepatitis C virus'.
    Gut. 2018 Jun 29. pii: gutjnl-2018-316438. doi: 10.1136/gutjnl-2018-316438.
    PubMed     Text format    


  16. NEGRO F
    Expanded benefits of curing the extrahepatic manifestations of HCV infection.
    Gut. 2018 Jun 5. pii: gutjnl-2018-316578. doi: 10.1136/gutjnl-2018-316578.
    PubMed     Text format    


    May 2018
  17. WANG K, Lu X, Zhou H, Gao Y, et al
    Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study.
    Gut. 2018 May 5. pii: gutjnl-2018-316204. doi: 10.1136/gutjnl-2018-316204.
    PubMed     Text format     Abstract available


  18. BERTOLETTI A, Kennedy PTF, Durantel D
    HBV infection and HCC: the 'dangerous liaisons'.
    Gut. 2018;67:787-788.
    PubMed     Text format    


    April 2018
  19. CACOUB P, Desbois AC, Comarmond C, Saadoun D, et al
    Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis.
    Gut. 2018 Apr 27. pii: gutjnl-2018-316234. doi: 10.1136/gutjnl-2018-316234.
    PubMed     Text format     Abstract available


  20. SHIHA G, Esmat G, Hassany M, Soliman R, et al
    Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut. 2018 Apr 17. pii: gutjnl-2017-315906. doi: 10.1136/gutjnl-2017-315906.
    PubMed     Text format     Abstract available


  21. LLIBRE A, Shimakawa Y, Mottez E, Ainsworth S, et al
    Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.
    Gut. 2018 Apr 3. pii: gutjnl-2017-315783. doi: 10.1136/gutjnl-2017-315783.
    PubMed     Text format     Abstract available


  22. GILL US, Pallett LJ, Kennedy PTF, Maini MK, et al
    Liver sampling: a vital window into HBV pathogenesis on the path to functional cure.
    Gut. 2018;67:767-775.
    PubMed     Text format     Abstract available


  23. TAN W, Xia J, Dan Y, Li M, et al
    Genome-wide association study identi fi es HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure.
    Gut. 2018;67:757-766.
    PubMed     Text format     Abstract available


    March 2018
  24. LIN HH, Tseng TC, Kao JH
    Large and middle hepatitis B surface antigen: the lower the better?
    Gut. 2018 Mar 7. pii: gutjnl-2018-316030. doi: 10.1136/gutjnl-2018-316030.
    PubMed     Text format    


    February 2018
  25. HEO MJ, Kim TH, You JS, Blaya D, et al
    Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression.
    Gut. 2018 Feb 23. pii: gutjnl-2017-315123. doi: 10.1136/gutjnl-2017-315123.
    PubMed     Text format     Abstract available


  26. MURATA K, Asano M, Matsumoto A, Sugiyama M, et al
    Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Gut. 2018;67:362-371.
    PubMed     Text format     Abstract available


    January 2018
  27. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    PubMed     Text format    


  28. IBRAHIM SH, Hirsova P, Gores GJ
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691.
    PubMed     Text format     Abstract available


  29. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.
    PubMed     Text format    


  30. KIM GA, Lim YS
    Response to: 'Prognosis of immune-tolerant phase chronic hepatitis B' by Chu and Liaw.
    Gut. 2018 Jan 13. pii: gutjnl-2017-315815. doi: 10.1136/gutjnl-2017-315815.
    PubMed     Text format    


    December 2017
  31. GIERSCH K, Bhadra OD, Volz T, Allweiss L, et al
    Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.
    Gut. 2017 Dec 7. pii: gutjnl-2017-314713. doi: 10.1136/gutjnl-2017-314713.
    PubMed     Text format     Abstract available


    November 2017
  32. WANG X, Yan Y, Gan T, Yang X, et al
    A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Gut. 2017 Nov 27. pii: gutjnl-2017-314870. doi: 10.1136/gutjnl-2017-314870.
    PubMed     Text format     Abstract available


  33. CHU CM, Liaw YF
    Prognosis of immune-tolerant phase chronic hepatitis B.
    Gut. 2017 Nov 25. pii: gutjnl-2017-315603. doi: 10.1136/gutjnl-2017-315603.
    PubMed     Text format    


  34. HILLAIRE S, Kahn JE, Picone O, Cazals-Hatem D, et al
    Rare cause of abdominal pain and fever in a pregnant woman.
    Gut. 2017;66:1911-1982.
    PubMed     Text format     Abstract available


    October 2017
  35. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Text format     Abstract available


    September 2017
  36. PFEFFERKORN M, Bohm S, Schott T, Deichsel D, et al
    Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers.
    Gut. 2017 Sep 26. pii: gutjnl-2017-313811. doi: 10.1136/gutjnl-2017-313811.
    PubMed     Text format     Abstract available


  37. WU T, Li J, Shao L, Xin J, et al
    Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    Gut. 2017 Sep 19. pii: gutjnl-2017-314641. doi: 10.1136/gutjnl-2017-314641.
    PubMed     Text format     Abstract available



  38. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed     Text format    


    August 2017
  39. HUANG F, Long F, Yu W, Situ J, et al
    High prevalence of hepatitis E virus in semen of infertile male and causes testis damage.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314884. doi: 10.1136/gutjnl-2017-314884.
    PubMed     Text format    


  40. ZHANG W, Sun M, Chen G, An Y, et al
    Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection.
    Gut. 2017 Aug 16. pii: gutjnl-2017-313896. doi: 10.1136/gutjnl-2017-313896.
    PubMed     Text format    


  41. THOMPSON A, Locarnini S, Revill P
    Reply: 'More viral mutants, less HBsAg clearance? One size may not fit all'.
    Gut. 2017;66:1534-1535.
    PubMed     Text format    


    July 2017
  42. PETTA S, Craxi A
    Can we prevent and modify cardiometabolic disorders by controlling HCV infection?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314505. doi: 10.1136/gutjnl-2017-314505.
    PubMed     Text format    


  43. NASSAL M
    Chronic hepatitis B: divide and conquer?
    Gut. 2017 Jul 13. pii: gutjnl-2017-314255. doi: 10.1136/gutjnl-2017-314255.
    PubMed     Text format    


  44. TSENG TC, Yang HC, Kao JH
    More viral mutants, less HBsAg clearance? One size may not fit all.
    Gut. 2017;66:1349.
    PubMed     Text format    


    June 2017
  45. LEVANDER S, Holmstrom F, Frelin L, Ahlen G, et al
    Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.
    Gut. 2017 Jun 23. pii: gutjnl-2016-313579. doi: 10.1136/gutjnl-2016-313579.
    PubMed     Text format     Abstract available


  46. MAHALE P, Engels EA, Li R, Torres HA, et al
    The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
    Gut. 2017 Jun 20. pii: gutjnl-2017-313983. doi: 10.1136/gutjnl-2017-313983.
    PubMed     Text format     Abstract available


  47. SUN HY, Cheng PN, Tseng CY, Tsai WJ, et al
    Favouring modulation of circulating lipoproteins and lipid loading capacity by direct antiviral agents grazoprevir/elbasvir or ledipasvir/sofosbuvir treatment against chronic HCV infection.
    Gut. 2017 Jun 14. pii: gutjnl-2017-313832. doi: 10.1136/gutjnl-2017-313832.
    PubMed     Text format     Abstract available


  48. SCHIAVON LL, Narciso-Schiavon JL, Ferraz MLG, Silva AEB, et al
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) in HBV patients: just adding up?
    Gut. 2017;66:1169-1170.
    PubMed     Text format    


    May 2017
  49. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
    PubMed     Text format    


    April 2017
  50. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Text format     Abstract available


  51. RAMACHANDRAN A, Jaeschke H
    PGAM5: a new player in immune-mediated liver injury.
    Gut. 2017;66:567-568.
    PubMed     Text format    


    March 2017
  52. COLPITTS CC, Tawar RG, Mailly L, Thumann C, et al
    Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Gut. 2017 Mar 30. pii: gutjnl-2016-312577. doi: 10.1136/gutjnl-2016-312577.
    PubMed     Text format     Abstract available


  53. LAURAIN A, Kramer L, Sultanik P, Vallet-Pichard A, et al
    Mortality associated with the treatment of HCV with direct-acting antivirals.
    Gut. 2017 Mar 23. pii: gutjnl-2017-313869. doi: 10.1136/gutjnl-2017-313869.
    PubMed     Text format    


  54. HERNAEZ R, Sola E, Moreau R, Gines P, et al
    Acute-on-chronic liver failure: an update.
    Gut. 2017;66:541-553.
    PubMed     Text format     Abstract available


    February 2017
  55. ARNOLD F, Patch D, Yu D, Westbrook RH, et al
    When banding fails; investigation hails.
    Gut. 2017;66:322.
    PubMed     Text format    


    January 2017
  56. LEMOINE M, Thursz M, Mallet V, Shimakawa Y, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference.
    Gut. 2017;66:195-196.
    PubMed     Text format    


    September 2016
  57. KUTTKAT N, Mohs A, Ohl K, Hooiveld G, et al
    Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease.
    Gut. 2016 Sep 29. pii: gutjnl-2015-311119. doi: 10.1136/gutjnl-2015-311119.
    PubMed     Text format     Abstract available


  58. DAHEIM M, Lang S, Goeser T, Steffen HM, et al
    Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia.
    Gut. 2016 Sep 26. pii: gutjnl-2016-312993. doi: 10.1136/gutjnl-2016-312993.
    PubMed     Text format    


    August 2016
  59. HE GW, Gunther C, Kremer AE, Thonn V, et al
    PGAM5-mediated programmed necrosis of hepatocytes drives acute liver injury.
    Gut. 2016 Aug 26. pii: gutjnl-2015-311247. doi: 10.1136/gutjnl-2015-311247.
    PubMed     Text format     Abstract available


    July 2016
  60. JENDREK ST, Gotthardt D, Nitzsche T, Widmann L, et al
    Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Gut. 2016 Jul 12. pii: gutjnl-2016-311739. doi: 10.1136/gutjnl-2016-311739.
    PubMed     Text format     Abstract available


    February 2016
  61. JAMIL KM, Hydes TJ, Cheent KS, Cassidy SA, et al
    STAT4-associated natural killer cell tolerance following liver transplantation.
    Gut. 2016 Feb 17. pii: gutjnl-2015-309395. doi: 10.1136/gutjnl-2015-309395.
    PubMed     Text format     Abstract available


  62. WIESER V, Adolph TE, Enrich B, Kuliopulos A, et al
    Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors.
    Gut. 2016 Feb 8. pii: gutjnl-2015-310344. doi: 10.1136/gutjnl-2015-310344.
    PubMed     Text format     Abstract available


    October 2015
  63. NAHON P, Lescat M, Layese R, Bourcier V, et al
    Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
    Gut. 2015 Oct 28. pii: gutjnl-2015-310275. doi: 10.1136/gutjnl-2015-310275.
    PubMed     Text format     Abstract available


    July 2015
  64. KENG CT, Sze CW, Zheng D, Zheng Z, et al
    Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection.
    Gut. 2015 Jul 6. pii: gutjnl-2014-307856. doi: 10.1136/gutjnl-2014-307856.
    PubMed     Text format     Abstract available


    June 2015
  65. LEMOINE M, Shimakawa Y, Nayagam S, Khalil M, et al
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa.
    Gut. 2015 Jun 24. pii: gutjnl-2015-309260. doi: 10.1136/gutjnl-2015-309260.
    PubMed     Text format     Abstract available


  66. ZHANG DY, Goossens N, Guo J, Tsai MC, et al
    A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.
    Gut. 2015 Jun 4. pii: gutjnl-2015-309655. doi: 10.1136/gutjnl-2015-309655.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: